Blue Owl Capital, an asset manager, and Canada Pension Plan Investment Board, a global investment management organization, agreed to invest $500m in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers. “We are excited to be working with a distinguished group of life sciences investors who are aligned with our view of acoramidis’ blockbuster market opportunity. Our newly strengthened balance sheet will enable us to serve ATTR-CM patients with a well-resourced launch of acoramidis, as well as patients with genetic diseases more broadly with multiple Phase 3 readouts for blockbuster indications anticipated over the next few years. Our increasing patient impact should allow us to diversify drivers of top line revenue in the near term and enable reinvestment into R&D paired with opportunistic business development,” Brian Stephenson, BridgeBio Pharma CFO.